RxDoctor Payments Data

Berenese Canady

Psychiatric/Mental Health · Memphis, TNNPI 1053616292

Payments from drug & device makers

$923in general payments, 2019–2025

Across 28 payments — averaging $32.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$340
  • Alkermes, Inc.$165
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$125
  • Neurocrine Biosciences, Inc.$121
  • Teva Pharmaceuticals USA, Inc.$120
  • Indivior Inc.$29
  • plus $23 from 1 others

What the payments were for

  • Food & beverage$923100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$923 in reported general payments places this provider in the 55th percentile of 1,167 psychiatric/mental health providers in Tennessee.

See all psychiatric/mental health providers in Tennessee

Medicare billing

Part B allowed, 2024
$18,955
Medicare patients
47
Services billed
241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AristadaAripiprazole Lauroxil18$58,666
VraylarCariprazine Hcl35$49,677
Invega SustennaPaliperidone Palmitate16$44,674
Abilify MaintenaAripiprazole14$40,554
RexultiBrexpiprazole12$19,805
Venlafaxine Hcl ErVenlafaxine Hcl42$6,099
ZoloftSertraline Hcl12$5,221
RisperdalRisperidone12$3,555
Aripiprazole61$3,378
Lurasidone Hcl37$2,772
Divalproex Sodium ErDivalproex Sodium47$2,481
KlonopinClonazepam12$2,115
Oxcarbazepine60$1,906
Desvenlafaxine Succinate ErDesvenlafaxine Succinate33$1,777
Carbamazepine ErCarbamazepine12$1,757

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alkermes, Inc.Aristada$165$58,66618 claims
AbbVieVraylar$340$49,67735 claims
Johnson & JohnsonInvega Sustenna, Risperdal$23$48,22928 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,167 psychiatric/mental health providers in Tennessee.

Other psychiatric/mental health in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →